Evidence map›Paper›PMID 41071101›Full record

ArticleGlycobiology2025

Editor's Choice Platform for identifying human glycan-specific antibodies against bacterial pathogens using synthetic glycan fragments.

A Robin Temming, Mathieu Claireaux, Gius Kerster, Silvie E Groenewege, Thijs Voskuilen, Zhen Wang, Jeroen D C Codée, Marit J van Gils, Nina M van Sorge

Abstract read
In one paragraph

Article in Glycobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. T cells in Group AFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A Robin TemmingDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.ORCID 0000-0002-4104-0522
Mathieu ClaireauxDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Gius KersterDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Silvie E GroenewegeDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Thijs VoskuilenLeiden Institute of Chemistry, Leiden University, Einsteinweg 55 2333 CC Leiden, The Netherlands.
Zhen WangLeiden Institute of Chemistry, Leiden University, Einsteinweg 55 2333 CC Leiden, The Netherlands.
Jeroen D C CodéeLeiden Institute of Chemistry, Leiden University, Einsteinweg 55 2333 CC Leiden, The Netherlands.
Marit J van GilsDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Nina M van SorgeDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.ORCID 0000-0002-2695-5863

Funding

Dutch Research CouncilNWO-Vicithe ZonMW-Vici 09150181910001
6 · The paper itself

Abstract

Bacterial infections represent a substantial global health challenge, impacting both human and veterinary health. The ongoing evolution of antibiotic-resistant pathogens, coupled with limited new antibiotic discoveries, urges the need for alternative strategies to treat and prevent these infections. Passive immunization with monoclonal antibodies (mAbs) is gaining interest as a promising alternative. Here, we report an experimental pipeline for generating human mAbs from healthy donor B cells using synthetic mimics of complex bacterial glycans. We identified functional mAbs recognizing discrete and unique epitopes on the surface glycans of two bacterial priority pathogens; Staphylococcus aureus and Streptococcus pyogenes. The use of chemically-defined synthetic glycans was critical for the discovery and systematic characterization of mAbs. From a heterogeneous mix of B cell specificities, antibody sequences were identified, leading to the production of mAbs with distinct reactivities against immunodominant but also to less common or even masked epitopes. The pipeline can be adapted to different glycan targets, donor material or specific antibody isotypes. This work thereby paves the way for the discovery of glycan-specific mAbs with clinical relevance to treat, prevent or diagnose infections with S. aureus, S. pyogenes or other bacterial pathogens.

Indexed as

Antibodies, BacterialAntibodies, MonoclonalPolysaccharidesStaphylococcus aureusStreptococcus pyogenesEpitopesHumansAntibodies, BacterialAntibodies, MonoclonalEpitopesPolysaccharidesantibody discoverybacterial glycansingle cell B cell receptor sequencingStaphylococcus aureusStreptococcus pyogenes

Identifiers

PMID41071101
PMCPMC12596258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.